Pharmacokinetic and Pharmacodynamic study of nab-Paclitaxel and solvent-based Paclitaxel in patients with metastatic or recurrent gastric cancer
Not Applicable
- Conditions
- Metastatic or recurrent gastric cancer
- Registration Number
- JPRN-UMIN000030277
- Lead Sponsor
- Shizuoka Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1) Active infection 2) Women who is pregnant, suspected of being pregnant, within 28 days of postparturition, or lactating 3) Coexisting psychiatric disease 4) Continuous use of immune-suppressive agent 5) Known hypersensitivity to paclitaxel or albumin compound
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Concentration of unbound paclitaxel and neutrophil count during 28 days from the commencement of nab-paclitaxel or solvent-based paclitaxel administration
- Secondary Outcome Measures
Name Time Method